Wall Street PR

Guided Therapeutics Rallies After CE Mark Approval (GTHP)

The share price of Guided Therapeutics (OTC: GTHP) rose today following the announcement of the company’s CE Mark Approval. The stock rallied a respectable 22%, and closed today’s trading session at a share price of $0.94. Volume of the stock spiked to a total of 446,518 shares, bypassing its average of 57,195 shares.

Today, July 18, 2012, Guided Therapeutics announced that it has received notification that CE Mark approval has been granted for its LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer.

Despite today’s rally, the stock has posted a loss of 38.2% year-to-date. The stock tanked significantly in January and has been trading near its low share price range since that time.

According to @pennystock24 on Twitter, Penny Stock Wizards, among others, promoted Guided Therapeutics today. Oddly, stockpromoters.com does not list any results for the promotion of Guided Therapeutics.

Here are some other notable headlines for Guided Therapeutics:

  • July 9, 2012: Guided Therapeutics announced the results of its previously announced exchange offer for certain outstanding warrants to purchase up to an aggregate of approximately 28.4 million shares of its common stock.
  • June 26, 2012: Guided Therapeutics announced that it had extended its licensing agreement to co-develop a non-invasive Barrett’s Esophagus detection product, for a third consecutive year, with Konica Minolta (OTC: KNCAY).
  • June 19, 2012: Guided Therapeutics announced that it, together with its Canadian distribution partner, CAN-med Healthcare, would be unveiling the LuViva® Advanced Cervical Scan at the 68th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada (SOGC) to be held in Ottawa, Ontario.

Guided Therapeutics, formerly SpectRx, incorporated on October 27, 1992, is a medical technology company focused on developing medical devices.

Guided Therapeutics’ primary focus is the development of its cervical cancer detection technology and extension of its cancer detection platform into other cancers, especially lung and esophageal.

The company competes with Johnson & Johnson, Roche Diagnostics, Bayer AG, Abbott, Dexcom, Cytyc Corporation, Digene Corporation and Medtronic MiniMed.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.